A revolutionary
integrated genomic and clinical
data source

Geneyx has developed a universal genomic data-source that is trustworthy, efficient and compliant with current strict medical-data privacy regulations. The Geneyx platform offers genetic testing labs and hospital-based facilities, as well as a secure, cloud-based data management and storage system. Geneyx enables Pharma, universities and institute based research groups to spearhead the development of innovative drugs, novel therapeutic and diagnostic tools for the benefit of human health and well-being, using Geneyx’s reliable and diverse genetic data.

Genome rush

In the era of the ever-increasing personalization of healthcare, genetic data has become the new driving force in the development of therapeutic measures and diagnostic tools, which in turn, creates a strong demand for high quality, reliable genetic data. Mapping the human genome and its importance in disease, beginning with the completion of the human genome project in late 2000, has revolutionized our ability to resolve, diagnose, and treat many diseases affecting the lives of billions of people. Both increased public awareness about the importance of genetic testing, and the steep decreases in the cost of these tests in recent years to currently under $1000, has made genetic sequencing more readily available to the public. These two aspects together, have resulted in a growing surge of clinically relevant genetic data production.

Mapping the human genome and its importance in disease, beginning with the completion of the human genome project in late 2000, has revolutionized our ability to resolve, diagnose, and treat many diseases affecting the lives of billions of people. Both increased public awareness about the importance of genetic testing, and the steep decreases in the cost of these tests in recent years to currently under $1000, has made genetic sequencing more readily available to the public. These two aspects together, have resulted in a growing surge of clinically relevant genetic data production.

We, the Geneyx team, are already dealing with big data in genetics, surpassing what has previously been considered big. Genetic labs all over the world are creating petabytes of stored genetic data, which is rapidly growing toward Exabyte.

The DNA code as is, exposes the genome owner’s identity and many clinically relevant features, making it not GDPR/HIPAA compliant when stored in a regular fashion. Genetic data is highly sensitive personal data; therefore, it calls for the strictest privacy regulations. It should be stored carefully and used with caution, but it must be used in order to drive forward novel discovery and ever improving human health. Our main challenge at Geneyx is maintaining a careful balance between privacy and accessibility of the clinically relevant genetic data.

Storage of sensitive info and unique processing requirements pose the pillar of this serious challenge. Our solution combines innovation in fields of encryption, cyber security, classification and indexing, augmented with an intuitive analysis platform that provides effective data access, and providing a modular toolkit for downstream analysis needs of our customers. Current repositories and analysis toolkits offer incomplete solutions. They lack the sufficient diversification to truly capture human ethnic and geographic diversity, thus prohibiting true personalization of health care. On the other hand, they may offer a good analysis toolkit, but without the secured and easy access to genetic and clinical meta-data. The Geneyx platform has been developed to form a bridge between these two aspects, by creating an innovative end-to-end solution, enabling the researcher to focus on the science.

Collapse

The DNA sequence is the only medical info that stays relevant to our health throughout life

Indexed database of
millions of genomes will pave the way to novel discoveries in personalized
health across the globe

Our customers

Geneyx is currently able to securely store and index the complete, immutable, validated genetic data with associated meta and clinical data.

The single data entry - The Genome Owner

The patient owns his data and reserves the right to either make it available selectively for prechosen purposes, such as research, or be completely removed from the data bank at any given time. The genetic information, as opposed to most other clinical readouts, is stable and does not change through one’s lifespan. When errors occur, in the case of cancer for example, the healthy genome snapshot is highly important. Additionally, a person's genetic information is useful to future generations and therefore expands one’s lifetime.

The data producer - The Genetic Lab

The genetic data is produced by a lab that provides sequencing services. Whether it is part of the referring medical organization or an outsourced service provider, the sequencing lab is the first link in the data chain-of-custody. They are required to produce and transfer the genetic data securely, or even store it for a certain period of time. No matter the scenario, Geneyx offers the lab a modular start-to-finish solution directly from the sequencer outputs, through a modular customizable processing pipeline, the clinical analysis toolkits and finally, the results formulated as reports to the patient (genome owner).

The medical professional - The Clinical staff

Once genetic sequencing has been done, the physician or genetic counselor should have access to their patients' genetic data and outputted reports in order to utilize the full personal clinical value,, assuming the physician has the capability to analyze the report himself. Most likely, the future of medicine will address this issue, and ideally, all physicians will have substantial training in genetics and data analysis. Currently, most physicians need such reports already analyzed. In addition, most medical care facilities do not have large enough storage facilities for analyzing genomic data.

The data consumer - Pharma and Research

Pharma and researchers are currently in the market for large aggregations of high-quality genetic data coupled with relevant clinical information. Meanwhile, the two main hurdles have been regulation and easy accessibility.

The value for the pharma and the academic research

Geneyx provides pharma companies, universities and research facilities with the most comprehensive, diversified and reliable genome-based databank supporting pre-clinical research, novel drug and therapeutics development.
With Geneyx’s solution, Pharma companies can decelerate the declining efficiency of every dollar spent on drugs R&D and start to increase ROI by finally, de-risking novel projects and putative drug leads using genomic-based analysis, all done without concern towards regulatory compliance on the researcher’s end.

Geneyx provides pharma companies, universities and research facilities with the most comprehensive, diversified and reliable genome-based databank supporting pre-clinical research, novel drug and therapeutics development.
With Geneyx’s solution, Pharma companies can decelerate the declining efficiency of every dollar spent on drugs R&D and start to increase ROI by finally, de-risking novel projects and putative drug leads using genomic-based analysis, all done without concern towards regulatory compliance on the researcher’s end.
Geneyx databank is based on aggregating datasets (human sequenced exomes/genomes) from dozens of genetic labs around the world. This model allows parallel and rapid additions of new and relevant genetic data points. Additionally, this model enables our data consumers (i.e. research groups) to formulate a partnership with Geneyx, aimed at target expansion of the data bank, to represent sub-populations and pathologies that are strictly under-represented at the time of request.
In order to drive meaningful research, genetic data has to be coupled with clinical and meta-data of the genome owner. Geneyx’s comprehensive genetic data bank is comprised not only of genetic data, but also of annotated clinical data (HPO) and the genome owner’s personal meta-data.
Geneyx’s unique genome-wide privacy protection technology (patent pending) makes our genetic data bank fully GDPR / HIPAA compliant, allowing pharma and academic research groups to concentrate solely on R&D, rather than on legal entanglements purposed only at securing that no infringement of the genome owner’s privacy has occurred.
Geneyx’s processing dashboard provides advanced query capabilities allowing researches to cross search meta-data, clinical data and genetic features, such as quality estimates, genomic coordinates etc. By doing so, researchers save time and computational resources on irrelevant data points and focus on targeting desired conditions only.
Geneyx’s platform includes a user customized virtual, cloud based, environment that enables efficient, rapid and accurate processing of genetic data. This mode of operation will increase research groups’ workflow efficiency and intergroup communication in genetic data driven projects. All this translates to saving time, money and eventually lives by expediting drug and therapeutics development at a pace like never before.

Collapse

The value for testing labs and hospitals

Geneyx developed an innovative solution to securely store and manage all data files related to genome sequencing. The data is stored on our virtual private cloud, strictly secured, yet accessible for various uses – for either the lab, or the genome owner (patient) and his medical care givers and for appendix future research.
Geneyx aspires to become a highly versatile and vast genomic data hub. Your lab’s past and future data and clientspatients could be a part of this revolutionary repository. This sort of Bio hubs are already a major force driving the world of therapy and drug development forward and are being sought after relentlessly. When data originating from your lab is picked up for a research project, either by pharma or by an academic research group both the lab and the genome owner are compensated.

Geneyx aspires to become a highly versatile and vast genomic data hub. Your lab’s past and future data and clients\patients could be a part of this revolutionary repository. This sort of Bio hubs are already a major force driving the world of therapy and drug development forward and are being sought after relentlessly. When data originating from your lab is picked up for a research project, either by pharma or by an academic research group both the lab and the genome owner are compensated.

Geneyx assures:

Substantial cost reduction, mainly on long term storage and data transfer.
Increasing lab profit margin
Compliance with patient data storage regulations
Optimizing the genetic consultation process
Improved customer service
Direct connection to sequencing machinery (Illumina or other)
Achieving simple interaction with various LIMS, or LIMS independent operations.

Collapse

Team

David Yizhar

CEO

Co-founder and CEO of Geneyx, is an investor and entrepreneur with over 40 years of experience in the international IVD and medical devices markets.

Co-founder and CEO of Geneyx, is an investor and entrepreneur with over 40 Years of experience in the international IVD and Medical devices markets. David is the consummate businessman, with the vision, drive and capabilities to found and lead a wide array of businesses and ventures, and indeed, has done so as a founder and CEO in Israel, East Europe, Italy and the Far East. David is an exemplary top executive, with the knowledge, acumen and fine-honed skills to passionately lead any company to achieve, and even surpass, their goals. Lately, he has been particularly active in the fields of molecular biology, genetics and NGS technology. David’s successful track record in managing multinational companies, raising funds, and bringing vision to fruition is noteworthy. David earned his MBA from Hebrew University in Jerusalem. David is a long run runner and has successfully completed dozens marathons and long run races. David brings sport dedication to his professional work.

Collapse

Avi Yitzhak

Cto

Co-founder and CTO of Geneyx, is an accomplished senior technology manager with hands-on knowledge in a wide array of technologies.

Co-founder and CTO of Geneyx, is an accomplished senior technology manager with hands-on knowledge in a wide array of technologies. He is technologically brilliant, with master knowledge in all programming languages. Avi brings more than 30 years of professional success, including as CTO, in a range of high-tech companies, from start-ups to large Nasdaq-listed corporations, such as Verint Systems. His accomplishments include leading 200 engineers in developing telecom network products and had overseen delivery and support of projects, generating over $100 million a year. AT&T and Vodafone are just two examples of his satisfied clients. He earned his MA degree in Clinical Psychology from Hebrew University in Jerusalem and this knowledge and experience has enhanced his success in his professional life and executive roles.

Collapse

Dvir Dahary

Cso

Co-founder and CSO of Geneyx, is one of the leading, veteran geneticists in Israel and holds seven patents in genomic analytics.

Co-founder and CSO of Geneyx, is one of the leading, veteran geneticists in Israel and holds seven patents in genomic analytics. He is an esteemed genetic analyst and developer, with over 15 years of experience in genomics and bioinformatics. As Chief Scientist at LifeMap Sciences, he developed a groundbreaking program for genome analysis. His outstanding work has contributed significantly to the analysis of NGS data for clinical diagnostics. Other key positions include co-founder and CEO of Toldot Genetics Ltd, Team Lead for genomic research at Compugen Ltd. Israel, Metagenomics Analyst at Kyowa Hakko, Japan, scientist at the Molecular Genetics Department at the Weizmann Institute, and Bioinformatician and researcher at the R&D laboratory of the Genetic Institute at Tel-Aviv Medical Center, Israel. Dvir holds a M.Sc. degree in Cell Research from Tel-Aviv University.

Collapse

Raviv Itzhaky

Cmo

Co-founder and CMO of Geneyx, is a leading advertising, marketing, and creative branding professional with more than 35 years of experience.

Co-founder and CMO of Geneyx, is a leading advertising, marketing, and creative branding professional with more than 35 years of experience. Raviv is diverse, fast thinking, articulate and visionary, bringing these qualities to fruition throughout his prolific career. His positions have included Deputy CEO of the Division of Strategy and Creative at Publicis-Ariely Advertising, Deputy Managing Director at McCann Erickson in Tel Aviv, CEO at IPG Advertising, CEO at Clouds Communication, Founder and CEO of “IcqTV” – the first-ever web TV, and Head of the Advertising program at Bezalel Academy. He was also a renowned lecturer at the Academic College of Management, and is the author of the popular thriller novel “Conversion“. Raviv has spent the last 10 years as a successful marketer for hi-tech start-up companies that are renowned in the international markets, such as INSHOO, Aquarius Engines, Anagog and Leantegra. Raviv is a veteran and accomplished marketing consultant, whose drive, creative approach and multi-faceted talents make him an integral part of business aspects of the company. Raviv earned his BA in Film and Philosophy from Tel Aviv University and his MBA from Ono Academic College.

Collapse

Dr. Ofer Barnea

US Branch

Co-founder of Geneyx, is an accomplished scientist with an impressive background in biotechnology engineering and human molecular genetics.

Co-founder of Geneyx, is an accomplished scientist with an impressive background in biotechnology engineering and human molecular genetics. Ofer is currently doing his post doctorate in San Francisco. In conjunction with his work in Geneyx, Ofer is leading a groundbreaking project in human genomics and assay development at UCSF’s Bioengineering and Therapeutic Science Department, one of the world’s leading institutes. Previously, Ofer spearheaded efforts for opening a hereditary deafness laboratory at Tel-Aviv University, which worked on high-throughput genomics, epigenetics, and genome editing. This resulted in a seminal paper in the field of hearing impairment epigenetics, which later led to numerous breakthroughs in the field. Outside of academia, Ofer served as the Section Head at an army R&D branch, working on non-conventional warfare defense. He is diverse in his capabilities, and has had successful experience in team building, leadership, project management with extremely short deadlines, international policy, and operational bridging.

Collapse

Dr. Ilan Gronau

Planning Algorithms

An algorithm designer at Geneyx, is an extraordinary and brilliant scientist, dedicated and outstandingly professional in all he does.

An algorithm designer at Geneyx, is an extraordinary and brilliant scientist, dedicated and outstandingly professional in all he does. Ilan specializes in the development and application of algorithms and statistical methods for analyzing DNA, sequenced by high throughput assays. He has an outstanding ability to understand the problem at hand and design the necessary algorithms for each challenge. He is exceptionally curious, always questioning and seeking applicable solutions. His research is in species evolution and human population genetics, and addresses broader theoretical aspects of statistical inference. For the past several years, Ilan has been the Head of the Master’s program in the Efi Arazi School of Computer Science. He holds a Ph.D. from the Technion and a M.Sc. from the Weizmann Institute. He completed his post doctorate at the Computational Biology Department at Cornell University.

Collapse

Yaara Unger

Bioinformatics Specialist

A bioinformatics specialist at Geneyx, is an expert bioinformatician and software engineer, fluent with NGS analysis and other bioinformatics tools.

A Bioinformatics Specialist at Geneyx, is an expert bioinformatician and software engineer, fluent with NGS analysis and other bioinformatics tools, in addition to Python, Perl, Object-Oriented Programming, and relational databases. Yaara is a brilliant algorithmist and computational genomist. She is creative, innovative and extraordinarily talented in finding accurate solutions to any challenge. She has vast industrial experience in biotech, as she developed computational genomics software at Evogene, leading start-to-finish development of various software components. Yaara earned her M.Sc in Life Sciences from the Weizmann Institute of Science and her B.Sc. in Computer Science and Life Sciences at the Hebrew University in Jerusalem.

Collapse

Gil Meller

CHIEF ARCHITECT

Chief Architect at Geneyx, has more than 20 years of experience in the IT industry, leading and managing big R&D and technology teams of over 90 engineers.

Chief Architect at Geneyx, has more than 20 years of experience in the IT industry, leading and managing big R&D and technology teams of over 90 engineers. Gil has an unusual ability to envision the endgame and has the ability to find effective solutions. Previously, Gil served as the R&D manager and CTO of several companies with over 300 employees, such as WPT Enterprises, Playtech, Anyoption, and Web3. He has vast knowledge of various technologies including Java, PHP, NodeJS, JS, Python, DB and Big Data (Redshift, Elastic search, MSSQL, MySQL, MongoDB, Redis), cloud computing and architecture. Gil holds B.Sc. and M.Sc. degrees from the Technion Institute in Software Engineering and Information Systems.a

Collapse

Asaf Porat

CFO

CFO of 2 startups in the Cannabis industry over the last 3 years.

Investment Banker with over 16 years of experience in capital markets. Specialized in funding, IPOs and M&A.

CFO of 2 startups in the Cannabis industry over the last 3 years.

Investment Banker with over 16 years of experience in capital markets. Specialized in funding, IPOs and M&A.

Previous member of the board of a TASE company.

CEO of an OTC company for 2 years.

Collapse

Advisory board

Christian Tidona, PhD

CEO, BioMed X, Germany

Christian Tidona is a biotech entrepreneur, business angel, and founder of the BioMed X Innovation Center in Heidelberg, Germany. He studied molecular biology and received his doctoral degree from the University of Heidelberg. Throughout his entire professional life, his focus has always been to foster innovation at the interface between academia and industry. Christian is a co-founder of the Health Axis Europe alliance between the European health innovation clusters in Leuven, Maastricht, Copenhagen, and Heidelberg. He is chairman of the Weizmann Young European Network (WYEN) and member of the International Board of the Weizmann Institute of Science in Israel.